Into the Homestretch—The HOC is Almost Here!
This month the faculty of Medscape’s Going Back to the Heart of Cardiology join us to share insights on the most critical new (and on the horizon) cardiology-related advances and what HOC attendees will come away with regarding these advances and more. Read, enjoy, and register! In our last issue, I spoke with the Chair of Medscape’s 4th Annual Going Back to the Heart of Cardiology, Dr. Robert Harrington, who sounded off candidly with quick insights on various personal and professional topics ranging from the ages of his youngest and oldest cardiac patient to the most misunderstood fact about the heart. If you missed it, click here!
Also check out this issue’s Pulse, with articles from the Journal of the American Heart Association, Circulation, European Heart Journal, Journal of the American College of Cardiology, Cardiology News, and New England Journal of Medicine.
Housekeeping: CME 2023—Add this to your calendar now and sign up for updates:
Going Back to the Heart of Cardiology Conference (4th Annual)
Saturday-Monday December 8-10, 2023; Anaheim, California
To register, click here!
- Sessions 1-6: Cardiopulmonary Failure; Atherosclerosis and Thrombosis; and Cardiometabolic Disease; Electrical Failure; Valvular Disease: Special Topics in Cardiology
- View Agenda: https://www.heartofcardio.com/agenda
- To register, click here!
Thank you to our thought leaders for their time and expertise as faculty and in this interview. Don’t forget to register here for Medscape’s 2023 Going Back to the Heart of Cardiology conference for the best 2023 CME opportunity available! Please contact me at colleen@cmhadvisors.com with any comments and/or suggestions! –Colleen Hutchins
Into the Homestretch— The HOC is Almost Here!
What do you anticipate attendees coming away with from the sessions you chair at the HOC?
Dr. Ann Curtis/ Arrhythmia Management Parts 1 & 2: We will cover key points in the just-released Atrial Fibrillation Guideline as well as sudden cardiac arrest: who’s at risk, approaches to treatment, and health equity in implantable device utilization.
Dr. Butler/ Cardiovascular Dysfunction Parts 1 & 2: The program is designed to give attendees a very comprehensive look at the latest in evaluation and management, drugs and devices, and specific forms of HF advances like amyloidosis or hypertrophic cardiomyopathy. In two relatively short sessions, the attendees will be updated on where the field of HF is in 2023.
Dr. Manesh Patel/ Cardiometabolic Disease Parts 1 & 2: Attendees will be able to put into context of their own practice the use of the many new therapies for diabetes and obesity, along with the multiple pathways and therapies now available to treat lipids and hypertension.
Dr. Harold Dauerman/ Valvular Heart Disease and the Aorta: A Heart Team Approach Parts 1 & 2: A better understanding of timing of intervention and contemporary treatment options for severe valvular and aortic heart disease.
What are some of the latest breakthroughs in cardiology and research that will be of great import to Heart of Cardiology attendees to return to their practices armed with practical and useful treatment information?
Dr. Butler: We have had some breakthrough therapies now in patients with HFpEF, amyloidosis, and hypertrophic cardiomyopathy - all forms of HF that until recently had no targeted therapies except symptom relief. Guidelines have also been recently updated. This is a great opportunity to discuss all these exciting advances.
Dr. Curtis: We will be meeting just after the new ACC/AHA/HRS Guidelines for the Diagnosis and Management of Atrial Fibrillation are released. We will be covering the latest recommendations on diagnosis, including recommendations for screening patients, risk factor management, anticoagulation, and treatment, including pharmacologic therapy and ablation.
Dr. Patel: Some of the key breakthroughs will be new therapies for resistant hypertension, new therapies for hyperlipidemia, and the most effective ways to implement lifestyle changes.
Dr. Dauerman: The latest trials leading to expansion of indications for percutaneous aortic, mitral and tricuspid valve therapies, as well as areas of where surgical approaches remain the standard of care.
The Pulse
Cardiology News: Invasive test may cut health care costs related to angina without obstructive CAD
Medical Intelligence Quiz: Fast Facts Friday: Heart Attack
Loading ...